We are currently explore PD-1 disruption of T cells by generating CTL targeting on specific tumor antigen, as previous studies reported that sustained expansion of PD-1-expressing CTLs may require continuous treatment to interrupt PD-1/PD-L1 co-stimulation27. This evidence concerns the gene CD274 and neoplasm.